Skip to main content

Advertisement

Table 1 A table showing the baseline demographics and initial treatment for each group

From: Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia

  e13a2 e14a2 p value
Number
 % 29% 71.0% n/a
 Exact 20 49
Age (years)
 Mean 45.0 54.57 0.043
 Median 46.0 59.0
 Range 4–81 5–80
Sex
 Male 75.0% 55.1% 0.125
 Female 25.0% 44.9%
Follow-up (months)
 Mean 33.85 27.24 0.192
 Median 37.5 23
 Range 1–70 3–76
Haemoglobin (g/l)
 Mean 113.5 121.3 0.134
 Range 86–148 64–158
White Cell Count
  (×109/l) 189.80 92.40 0.0002
 Mean 49.1–563 4.86–292
 Range   
Platelets (×109/l)
 Mean 308 644 0.001
 Range 93–1058 178–2507
EUTOS SCORE
 Number available 15 42 0.685
 Average Score 35.93 39.66
 % High Risk 5.0% 6.1%
BCR-ABL1 PCR level
 Number available 17 42 0.354
 Mean 58.64% 71.0%
 Range 25.6–112 8.1–344
Initial Treatment
 Imatinib 400 mg/day 90% 93.9% n/a
 Imatinib 300 mg/day 5% 0%
 Imatinib 200 mg/day 5% 6.1%